A Phase 2 study of Tivozanib in Biliary Tract Cancers
Recruiting Phase 1,Phase 2 NCT04645160
Study Description
Evaluating the Safety and Effectiveness of Tivozanib in Treating Biliary Tract Cancers
Study Details
- Registry ID:
- NCT04645160
- Conditions:
- Cholangiocarcinoma, Bile Duct Neoplasm, Biliary Tract Malignancy
- Phase:
- Phase 1,Phase 2
- Target Enrollment:
- 31 participants
- Start Date:
- Age Range:
- 18–999 years
- Healthy Volunteers:
- No
Study Locations (1 site)
-
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.